Payment overview · 2025
General Payments
$18.64
1 reported records · 1 companies
Healthcare provider profile · identity verified
David Glenn Parker, MD
Allopathic & Osteopathic Physicians|Family Medicine · MARION, VA · NPI 1255370003
Verified facts
What the public records show
CMS Open Payments records show David Glenn Parker, MD received $18.64 in general payments during 2025 across 1 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 384 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.64 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $18.64 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
384 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 506 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 409 | 61 |
| Enulose | Lactulose | 393 | 28 |
| Eliquis | Apixaban | 384 | 29 |
| Furosemide | Furosemide | 306 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 290 | 34 |
| Lisinopril | Lisinopril | 280 | 40 |
| Potassium Chloride | Potassium Chloride | 279 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 241 | 31 |
| Divalproex Sodium | Divalproex Sodium | 209 | 31 |
| Metformin Hcl | Metformin Hcl | 203 | 29 |
| Metronidazole | Metronidazole | 177 | 12 |
| Donepezil Hcl | Donepezil Hcl | 168 | 20 |
| Mirtazapine | Mirtazapine | 145 | 21 |
| Trazodone Hcl | Trazodone Hcl | 142 | 25 |
| Buspirone Hcl | Buspirone Hcl | 139 | 24 |
| Losartan Potassium | Losartan Potassium | 131 | 21 |
| Sertraline Hcl | Sertraline Hcl | 129 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 28 |
| Benztropine Mesylate | Benztropine Mesylate | 125 | 19 |
| Levetiracetam | Levetiracetam | 124 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 111 | 25 |
| Glipizide | Glipizide | 108 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 100 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 11 |
| Gabapentin | Gabapentin | 94 | 27 |
| Risperidone | Risperidone | 92 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 14 |
| Simvastatin | Simvastatin | 83 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 69 | 15 |
| Baclofen | Baclofen | 68 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 62 | suppressed |
| Memantine Hcl | Memantine Hcl | 62 | suppressed |
| Omeprazole | Omeprazole | 61 | 26 |
| Propranolol Hcl | Propranolol Hcl | 61 | suppressed |
| Carvedilol | Carvedilol | 60 | 11 |
| Xifaxan | Rifaximin | 59 | suppressed |
| Olanzapine | Olanzapine | 58 | suppressed |
| Aripiprazole | Aripiprazole | 56 | 12 |
| Lorazepam | Lorazepam | 54 | 14 |
| Lactulose | Lactulose | 51 | suppressed |
| Meloxicam | Meloxicam | 50 | suppressed |
| Allopurinol | Allopurinol | 48 | suppressed |
| Spironolactone | Spironolactone | 47 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Prednisone | Prednisone | 42 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Naproxen | Naproxen | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 12 |
| Permethrin | Permethrin | 40 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 23 |
| Diltiazem 24hr Er | Diltiazem Hcl | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 37 | 24 |
| Haloperidol | Haloperidol | 37 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 37 | suppressed |
| Methimazole | Methimazole | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Clozapine | Clozapine | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 35 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 33 | suppressed |
| Humulin R | Insulin Regular, Human | 33 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 33 | suppressed |
| Trimethoprim | Trimethoprim | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Scopolamine | Scopolamine | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Erythromycin | Erythromycin Base | 26 | suppressed |
| Paliperidone Er | Paliperidone | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 23 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 12 |
| Versacloz | Clozapine | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Acitretin | Acitretin | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18.64 · 1 records | PFIZER INC. | ZAVZPRET | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error